While both Beam Therapeutics and Wave Life Sciences touted notable biomarker benefits for their respective alpha-1 ...

UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study ...

BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative ...

Far fewer companies are letting employees go so far in 2026 compared to 2025, but the number of people affected is trending ...

Analysts are extremely encouraged by Phase 2 trial results for Relay Therapeutics’ PI3KA inhibitor in treating vascular ...

Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial ...

Nusano will bring a massive new radioisotope facility in Salt Lake City online by the end of the year, establishing a supply ...

Biotech is increasingly financed, governed and regulated as though it were a mature pharmaceutical industry rather than a ...

A month after reporting that its RAS inhibitor daraxonrasib doubled survival in advanced pancreatic cancer, Truist said ...

Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve ...

BioSpace examines how the FDA approval of Eli Lilly’s oral obesity drug Foundayo has ignited a key race with Novo Nordisk.

While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted ...